Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
751 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01572038 | A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer(PERUSE) | completed | Phase 3 | 1,436 | Hoffmann-La RocheINDUSTRY | 39 | Sep 25, 2020 | clinicaltrials |
| NCT02264574 | A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | completed | Phase 3 | 229 | Pharmacyclics LLC. |
| 16 |
| Sep 21, 2020 |
| clinicaltrials |
| NCT02395172 | Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) | completed | Phase 3 | 792 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 29 | Aug 3, 2020 | clinicaltrials |
| NCT02718417 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | terminated | Phase 3 | 998 | PfizerINDUSTRY | 25 | Jul 14, 2020 | clinicaltrials |
| NCT02545504 | Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma(GAMMA-1) | completed | Phase 3 | 432 | Gilead SciencesINDUSTRY | 16 | May 26, 2020 | clinicaltrials |
| NCT03176238 | Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer(EVEREXES) | completed | Phase 3 | 235 | Novartis PharmaceuticalsINDUSTRY | 13 | Apr 7, 2020 | clinicaltrials |
| NCT01023308 | Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma(PANORAMA-1) | completed | Phase 3 | 767 | Novartis PharmaceuticalsINDUSTRY | 34 | Mar 17, 2020 | clinicaltrials |
| NCT01569295 | Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )(Tugela) | completed | Phase 3 | 416 | Gilead SciencesINDUSTRY | 18 | Mar 10, 2020 | clinicaltrials |
| NCT01611090 | A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 578 | Janssen Research & Development, LLCINDUSTRY | 21 | Mar 3, 2020 | clinicaltrials |
| NCT02301624 | Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis | completed | Phase 3 | 117 | Alexion Pharmaceuticals, Inc.INDUSTRY | 17 | Feb 5, 2020 | clinicaltrials |
| NCT02272413 | Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer | completed | Phase 3 | 671 | Boehringer IngelheimINDUSTRY | 28 | Jan 13, 2020 | clinicaltrials |
| NCT02008227 | A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy(OAK) | completed | Phase 3 | 1,225 | Hoffmann-La RocheINDUSTRY | 31 | Dec 20, 2019 | clinicaltrials |
| NCT02354508 | Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues | completed | Phase 3 | 123 | Novartis PharmaceuticalsINDUSTRY | 15 | Dec 10, 2019 | clinicaltrials |
| NCT01905943 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | completed | Phase 3 | 979 | Hoffmann-La RocheINDUSTRY | 31 | Oct 28, 2019 | clinicaltrials |
| NCT00917384 | Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | completed | Phase 3 | 355 | Eli Lilly and CompanyINDUSTRY | 30 | Sep 25, 2019 | clinicaltrials |
| NCT01168973 | A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy | completed | Phase 3 | 1,253 | Eli Lilly and CompanyINDUSTRY | 27 | Sep 25, 2019 | clinicaltrials |
| NCT01721044 | A Moderate to Severe Rheumatoid Arthritis Study(RA-BEACON) | completed | Phase 3 | 527 | Eli Lilly and CompanyINDUSTRY | 22 | Sep 18, 2019 | clinicaltrials |
| NCT00078260 | A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer | completed | Phase 3 | 589 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 12, 2019 | clinicaltrials |
| NCT00087711 | A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer | completed | Phase 3 | 1,713 | Eli Lilly and CompanyINDUSTRY | 27 | Sep 12, 2019 | clinicaltrials |
| NCT01818752 | Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma(CLARION) | completed | Phase 3 | 955 | AmgenINDUSTRY | 30 | Aug 26, 2019 | clinicaltrials |
| NCT02302807 | A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] | completed | Phase 3 | 931 | Hoffmann-La RocheINDUSTRY | 29 | Aug 1, 2019 | clinicaltrials |
| NCT01039376 | Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy(PROLONG) | terminated | Phase 3 | 480 | Novartis PharmaceuticalsINDUSTRY | 25 | Jul 30, 2019 | clinicaltrials |
| NCT01125566 | LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment | completed | Phase 3 | 508 | Boehringer IngelheimINDUSTRY | 38 | Jul 18, 2019 | clinicaltrials |
| NCT01997229 | Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) | completed | Phase 3 | 125 | Alexion Pharmaceuticals, Inc.INDUSTRY | 21 | Jul 16, 2019 | clinicaltrials |
| NCT01892345 | A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) | terminated | Phase 3 | 143 | Alexion Pharmaceuticals, Inc.INDUSTRY | 18 | Jun 26, 2019 | clinicaltrials |
| NCT01308567 | Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer(FIRSTANA) | completed | Phase 3 | 1,168 | SanofiINDUSTRY | 25 | Jun 5, 2019 | clinicaltrials |
| NCT01853319 | Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy(REGARD) | completed | Phase 3 | 100 | BayerINDUSTRY | 1 | Apr 22, 2019 | clinicaltrials |
| NCT02472145 | An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | completed | Phase 2 / Phase 3 | 326 | Janssen Research & Development, LLCINDUSTRY | 14 | Mar 19, 2019 | clinicaltrials |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | terminated | Phase 2 / Phase 3 | 545 | Boehringer IngelheimINDUSTRY | 27 | Mar 18, 2019 | clinicaltrials |
| NCT01243944 | Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | completed | Phase 3 | 222 | Incyte CorporationINDUSTRY | 18 | Mar 6, 2019 | clinicaltrials |
| NCT01523587 | LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy | completed | Phase 3 | 795 | Boehringer IngelheimINDUSTRY | 23 | Feb 15, 2019 | clinicaltrials |
| NCT02364999 | A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC | completed | Phase 3 | 719 | PfizerINDUSTRY | 27 | Feb 7, 2019 | clinicaltrials |
| NCT00574873 | Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML | completed | Phase 3 | 502 | PfizerINDUSTRY | 29 | Jan 8, 2019 | clinicaltrials |
| NCT00876395 | Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer(BOLERO-1) | completed | Phase 3 | 719 | Novartis PharmaceuticalsINDUSTRY | 28 | Dec 19, 2018 | clinicaltrials |
| NCT00789373 | A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 939 | Eli Lilly and CompanyINDUSTRY | 15 | Dec 14, 2018 | clinicaltrials |
| NCT01200758 | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 410 | Hoffmann-La RocheINDUSTRY | 30 | Nov 27, 2018 | clinicaltrials |
| NCT01482962 | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | completed | Phase 3 | 271 | Millennium Pharmaceuticals, Inc.INDUSTRY | 31 | Jul 31, 2018 | clinicaltrials |
| NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 487 | Millennium Pharmaceuticals, Inc.INDUSTRY | 29 | Jul 12, 2018 | clinicaltrials |
| NCT00003888 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer | completed | Phase 3 | 359 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 15 | Jul 9, 2018 | clinicaltrials |
| NCT01767467 | Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers | completed | Phase 3 | 568 | GlaxoSmithKlineINDUSTRY | 21 | Jun 6, 2018 | clinicaltrials |
| NCT01571284 | Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen | completed | Phase 3 | 781 | SanofiINDUSTRY | 23 | Apr 17, 2018 | clinicaltrials |
| NCT01137682 | Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly(PAOLA) | completed | Phase 3 | 198 | Novartis PharmaceuticalsINDUSTRY | 18 | Apr 5, 2018 | clinicaltrials |
| NCT00950300 | A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer | completed | Phase 3 | 596 | Hoffmann-La RocheINDUSTRY | 26 | Jan 23, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials